Identifying Non-mutational p53 Deficiency in Human Cancers
Author Information
Author(s): Qianpeng Li, Yang Zhang, Sicheng Luo, Zhang Zhang, Ann L Oberg, David E Kozono, Hua Lu, Jann N Sarkaria, Lina Ma, Liguo Wang
Primary Institution: National Genomics Data Center, China National Center for Bioinformation
Hypothesis
Both mutational and non-mutational inactivation of p53 could be reflected by the altered expression of genes regulated by p53.
Conclusion
The study reveals that a significant proportion of tumors with wild-type TP53 actually have compromised p53 function, which is associated with worse patient outcomes.
Supporting Evidence
- 87%–99% of TP53WT tumors were predicted to have reduced p53 function.
- Patients with TP53WT-pRF tumors had significantly shorter overall survival compared to those with TP53WT-pN tumors.
- TP53WT-pRF tumors exhibited increased genomic instability and hypoxia levels.
Takeaway
Some cancers have a normal-looking p53 gene, but it doesn't work properly, which can make the cancer worse and affect treatment.
Methodology
The study used support vector machine models to analyze gene expression data from multiple cancer types to assess p53 functionality.
Potential Biases
Potential bias from using a pan-cancer model that may be dominated by larger cancer types.
Limitations
The study's predictions are based on inferred p53 statuses rather than definitive measurements.
Participant Demographics
The study included data from multiple cancer types, primarily focusing on lung and breast cancers.
Statistical Information
P-Value
0.016
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website